Literature DB >> 26000505

Trends in relative survival for ovarian cancer from 1975 to 2011.

Jason D Wright1, Ling Chen, Ana I Tergas, Sonali Patankar, William M Burke, June Y Hou, Alfred I Neugut, Cande V Ananth, Dawn L Hershman.   

Abstract

OBJECTIVE: To examine relative survival (a metric that incorporates changes in survival within a population) in women with ovarian cancer from 1975 to 2011.
METHODS: Women diagnosed with ovarian cancer from 1975 to 2011 and recorded in the National Cancer Institute's Surveillance, Epidemiology, and End Results database were examined. Relative survival, estimated as the ratio of the observed survival of cancer patients (all-cause mortality) to the expected survival of a comparable group from the general population, was matched to the patients with the main factors that are considered to affect patient survival such as age, calendar time, and race. Hazard ratios were adjusted for age, race, year of diagnosis, time since diagnosis, and the interaction of age and years since diagnosis (except for stage II).
RESULTS: A total of 49,932 women were identified. For stage I ovarian cancer, the adjusted excess hazard ratio for death in 2006 was 0.51 (95% confidence interval [CI] 0.41-0.63) compared with those diagnosed in 1975. The reduction in excess mortality remained significant when compared with 1980 and 1985. For women with stage III-IV tumors, the excess hazard of mortality was lower in 2006 compared with all other years of study ranging from 0.49 (95% CI 0.44-0.55) compared with 1975 to 0.93 (95% CI 0.87-0.99) relative to 2000. For women aged 50-59 years, 10-year relative survival was 0.85 (99% CI 0.61-0.95) for stage I disease and 0.18 (99% CI 0.10-0.27) for stage III-IV tumors. For women aged 60-69 years, the corresponding 10-year relative survival estimates were 0.89 (99% CI 0.58-0.98) and 0.15 (99% CI 0.09-0.21).
CONCLUSION: Relative survival has improved for all stages of ovarian cancer from 1975 to 2011. LEVEL OF EVIDENCE: II.

Entities:  

Mesh:

Year:  2015        PMID: 26000505      PMCID: PMC4484269          DOI: 10.1097/AOG.0000000000000854

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  35 in total

1.  The Experience of Being Aware of Disease Status in Women with Recurrent Ovarian Cancer: A Phenomenological Study.

Authors:  Catherine Scott Finlayson; Mei R Fu; Allison Squires; Allison Applebaum; Janet Van Cleave; Roisin O'Cearbhaill; Antonio P DeRosa
Journal:  J Palliat Med       Date:  2018-11-08       Impact factor: 2.947

2.  Disparities in ovarian cancer survival in the United States (2001-2009): Findings from the CONCORD-2 study.

Authors:  Sherri L Stewart; Rhea Harewood; Melissa Matz; Sun Hee Rim; Susan A Sabatino; Kevin C Ward; Hannah K Weir
Journal:  Cancer       Date:  2017-12-15       Impact factor: 6.860

Review 3.  Epithelial ovarian cancer: the molecular genetics of epithelial ovarian cancer.

Authors:  J Krzystyniak; L Ceppi; D S Dizon; M J Birrer
Journal:  Ann Oncol       Date:  2016-04       Impact factor: 32.976

4.  Cisplatin induces the release of extracellular vesicles from ovarian cancer cells that can induce invasiveness and drug resistance in bystander cells.

Authors:  Priya Samuel; Laura Ann Mulcahy; Fiona Furlong; Helen O McCarthy; Susan Ann Brooks; Muller Fabbri; Ryan Charles Pink; David Raul Francisco Carter
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2018-01-05       Impact factor: 6.237

5.  Improvement in sexual function after ovarian cancer: Effects of sexual therapy and rehabilitation after treatment for ovarian cancer.

Authors:  Sharon L Bober; Christopher J Recklitis; Alexis L Michaud; Alexi A Wright
Journal:  Cancer       Date:  2017-09-07       Impact factor: 6.860

6.  Evolving population-based statistics for rare epithelial ovarian cancers.

Authors:  Koji Matsuo; Hiroko Machida; Shinya Matsuzaki; Brendan H Grubbs; Maximilian Klar; Lynda D Roman; Anil K Sood; David M Gershenson; Jason D Wright
Journal:  Gynecol Oncol       Date:  2020-01-15       Impact factor: 5.482

7.  Conditional Relative Survival of Ovarian Cancer: A Korean National Cancer Registry Study.

Authors:  Dong Wook Shin; Jaeman Bae; Johyun Ha; Kyu-Won Jung
Journal:  Front Oncol       Date:  2021-04-28       Impact factor: 6.244

Review 8.  Improving outcomes for older women with gynaecological malignancies.

Authors:  Lucy Dumas; Alistair Ring; John Butler; Tania Kalsi; Danielle Harari; Susana Banerjee
Journal:  Cancer Treat Rev       Date:  2016-08-29       Impact factor: 12.111

9.  MicroRNA-572/hMOF/Sirt6 regulates the progression of ovarian cancer.

Authors:  Mingbo Cai; Zhenhua Hu; Liping Han; Ruixia Guo
Journal:  Cell Cycle       Date:  2020-08-23       Impact factor: 4.534

10.  Management of advanced ovarian cancer in Spain: an expert Delphi consensus.

Authors:  Andres Redondo; Ana Oaknin; Maria Jesus Rubio; Maria-Pilar Barretina-Ginesta; Ana de Juan; Luis Manso; Ignacio Romero; Cristina Martin-Lorente; Andres Poveda; Antonio Gonzalez-Martin
Journal:  J Ovarian Res       Date:  2021-05-26       Impact factor: 4.234

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.